Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
Recruiting now · Phase 2
Conditions studied: Small Cell Lung Cancer, Renal Cell Carcinoma (RCC), Non-Small Cell Lung
In brief
This trial is a Phase II trial designed to evaluate the safety and efficacy of using oral AL8326 , a multi-targeted receptor Tyrosine Kinase Inhibitor( TKI) , to recurrent, advanced, or metastatic small cell lung cancer (SCLC) patients , Non-Small Cell Lung (NSCLC) and Renal Cell Carcinoma patients who need ≥2nd line treatment .
Key facts
- Study ID
- NCT05363280
- Run by
- Advenchen Pharmaceuticals, LLC.
- People needed
- 80
- Starts
- 2022-11-01
- Expected to finish
- 2028-12-01
- Last updated by the study team
- 2026-05-08
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Siteman Cancer Center, Washington University — St Louis, Missouri, United States (enrolling)
- Hospital Universitari Vall d'Hebron — Barcelona, Spain (enrolling)
- Hospital Universitario Ramón Y Cajal — Madrid, Spain (enrolling)
- University of Alabama at Birmingham — Birmingham, Alabama, United States (enrolling)
- Cleveland Clinic — Cleveland, Ohio, United States (enrolling)
- Cleveland Clinic Florida — Weston, Florida, United States
- Northwestern University — Chicago, Illinois, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.